Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Published
Journal Article (Review)
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
Full Text
Duke Authors
Cited Authors
- Roe, MT; Sapp, SK; Lincoff, AM
Published Date
- February 2000
Published In
Volume / Issue
- 67 / 2
Start / End Page
- 131 - 140
PubMed ID
- 10680279
Pubmed Central ID
- 10680279
International Standard Serial Number (ISSN)
- 0891-1150
Digital Object Identifier (DOI)
- 10.3949/ccjm.67.2.131
Language
- eng
Conference Location
- United States